Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects.

This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single‐center, open‐label, two‐period study. In period 1, epoprostenol 8 ng/kg/min was administered alone. In period 2, epoprostenol 8 ng/kg/min was administered following an 8‐...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacology Vol. 64; no. 11; pp. 1361 - 1373
Autores principales: Fonseca, Marlene, Guimarães, Andreia, Gama, Helena, Magalhães, Luís, Henriques, Sara Carolina, Silva, Nuno, Almeida, Luis, Soares‐da‐Silva, Patrício
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Nov2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=180503470&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 180503470
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00912700
        5WH
      jtl: Journal of Clinical Pharmacology
      issn: 00912700
      maglogo: Y
    pubinfo:
      dt: Nov2024
      vid: 64
      iid: 11
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        180503470
        178042994
        180503470
        180503470
        10.1002/jcph.2486
        180503470
      ppf: 1361
      ppct: 12
      formats:
      tig:
        atl: Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects.
      aug:
        au:
          Fonseca, Marlene
          Guimarães, Andreia
          Gama, Helena
          Magalhães, Luís
          Henriques, Sara Carolina
          Silva, Nuno
          Almeida, Luis
          Soares‐da‐Silva, Patrício
        affil: BlueClinical Phase I, Porto, Portugal
      sug:
        subj:
          Epoprostenol Administration and Dosage
          Infusions, Intravenous
          Oxidoreductases Antagonists and Inhibitors
          Dopamine Uptake Inhibitors Administration and Dosage
          Administration, Oral
          Drug Interactions Evaluation
          Epoprostenol Pharmacokinetics
          Dopamine Uptake Inhibitors Pharmacokinetics
          Epoprostenol Pharmacodynamics
          Dopamine Uptake Inhibitors Pharmacodynamics
          Human
          Drug Tolerance
          Metabolites
          Confidence Intervals
          Epoprostenol Metabolism
          Dopamine Uptake Inhibitors Metabolism
          Descriptive Statistics
          Cardiovascular System Drug Effects
          Biological Availability
          Funding Source
      ab: This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single‐center, open‐label, two‐period study. In period 1, epoprostenol 8 ng/kg/min was administered alone. In period 2, epoprostenol 8 ng/kg/min was administered following an 8‐day treatment with zamicastat. Since the initial dose of epoprostenol showed to be insufficiently tolerated, it was decreased to 6 ng/kg/min. Blood samples were collected to determine the metabolites of epoprostenol and concentrations of zamicastat and its metabolites. A total of 54 subjects were enrolled and data from 28 subjects were available for pharmacokinetic analysis. The epoprostenol plus zamicastat‐to‐epoprostenol geometric means ratio (GMR) and corresponding 90% confidence interval (CI) for Cav,ss and area under the plasma concentration–time curve from time 0 up to 16 h at steady state (AUC0‐16,ss) of the metabolites of epoprostenol were within the acceptance bioequivalence range (80.00%‐125.00%). The intrasubject coefficient of variation (ISCV) was below 10% for both parameters, on both metabolites. For zamicastat AUC0‐τ,ss, the zamicastat plus epoprostenol‐to‐zamicastat GMR and corresponding 90% CI were within the bioequivalence acceptance range, while for zamicastat Cmax,ss, the lower limit of the 90% CI was slightly below the acceptance range. For zamicastat metabolites, Cmax,ss and AUC0‐τ,ss and the zamicastat plus epoprostenol‐to‐zamicastat GMR were below the acceptance bioequivalence range. ISCV was between 30% and 41% for Cmax,ss and between 21% and 41% for AUC0‐τ,ss, for zamicastat and both metabolites. This study showed that the administration of zamicastat did not significantly modify the cardiovascular effects of epoprostenol and that the interactions between zamicastat and epoprostenol are not expected to be clinically relevant.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N